ArticleOpen access rheumatology : research and reviews2026
Treat-to-Target Strategy Achieves High Remission Rates with Sex Differences Attenuated Under Treat-to-Target Management in Rheumatoid Arthritis: A Longitudinal Analysis From the Rheumatoid Arthritis Saudi Database (RASD).
Article in Open access rheumatology : research and reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Rheumatoid arthritis (RA) affects women two-three times more frequently than men, and registries report sex-based differences in disease activity and remission. However, sex-stratified outcome data from Saudi Arabia are limited. We evaluated sex differences in disease activity, remission rates, and predictors of remission in the Rheumatoid Arthritis Saudi Database (RASD). Patients and Methods: We conducted a prospective cohort study of 647 patients with RA receiving biological or targeted synthetic DMARDs (574 female and 73 male) with at least 12 months of follow-up. Disease activity was assessed using DAS28-CRP, CDAI, FSS, and HAQ-DI across three visits. Remission was defined as DAS28-CRP <2.6. Linear mixed-effects models examined disease activity trajectories by sex, and multivariable logistic regression identified predictors of remission at visit 3. Benjamini-Hochberg correction was applied across six Stage-4 chi-square tests and across three pairwise sex comparisons within each outcome. Results: Overall remission rates rose from 50.9% at visit 1 to 83.5% at visit 3, with no significant sex differences after correction for multiple comparisons. DAS28-CRP declined significantly over time in both sexes (p <0.001). Males had higher adjusted CDAI at Visit 1 (13.43 vs 11.12; BH-adjusted p = 0.007), but not at visits 2 or 3; the visit-by-sex interaction was significant (unadjusted Type III p = 0.032). Fatigue and functional disability did not differ by sex. ACPA positivity was associated with higher odds of remission (OR 1.67, 95% CI 1.03-2.68, p = 0.036), while RF positivity was associated with lower odds (OR 0.61, 95% CI 0.38-0.96; p = 0.034). Sex was not an independent predictor. Conclusion: In this Saudi RA cohort, both sexes achieved high remission rates under treat-to-target management, and sex differences in disease activity did not persist after multiple-comparison correction. RF and ACPA, rather than sex, were the dominant predictors of remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.